CA2720124C - Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry - Google Patents
Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry Download PDFInfo
- Publication number
- CA2720124C CA2720124C CA2720124A CA2720124A CA2720124C CA 2720124 C CA2720124 C CA 2720124C CA 2720124 A CA2720124 A CA 2720124A CA 2720124 A CA2720124 A CA 2720124A CA 2720124 C CA2720124 C CA 2720124C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- sample
- drug
- adc
- mmae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5272708P | 2008-05-13 | 2008-05-13 | |
| US61/052,727 | 2008-05-13 | ||
| PCT/US2009/043560 WO2009140242A1 (en) | 2008-05-13 | 2009-05-12 | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2720124A1 CA2720124A1 (en) | 2009-11-19 |
| CA2720124C true CA2720124C (en) | 2015-07-21 |
Family
ID=40972862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2720124A Active CA2720124C (en) | 2008-05-13 | 2009-05-12 | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8541178B2 (https=) |
| EP (1) | EP2277044B1 (https=) |
| JP (1) | JP5539971B2 (https=) |
| AU (1) | AU2009246516B2 (https=) |
| CA (1) | CA2720124C (https=) |
| ES (1) | ES2544971T3 (https=) |
| WO (1) | WO2009140242A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| EP2398504B1 (en) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| KR102023496B1 (ko) * | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| KR101992502B1 (ko) | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
| CA2848520C (en) * | 2011-09-29 | 2019-11-26 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
| RU2638812C2 (ru) * | 2012-03-08 | 2017-12-15 | Ф. Хоффманн-Ля Рош Аг | Мультиплексный иммунохроматографический способ определения циркулирующих иммунокомплексов |
| CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP3933384A1 (en) | 2013-03-15 | 2022-01-05 | Hycor Biomedical, LLC | Device and associated method for performing luminescence and fluorescence measurements of a sample |
| GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
| US9758588B2 (en) | 2013-09-30 | 2017-09-12 | Becton, Dickinson And Company | Blocking reagent compositions and methods of making and using the same |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| TWI853985B (zh) | 2013-12-04 | 2024-09-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| LT3424955T (lt) | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| CN104974252B (zh) * | 2014-04-01 | 2020-04-24 | 三生国健药业（上海）股份有限公司 | 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途 |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| CN113933504A (zh) | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
| BR112017004810A2 (pt) * | 2014-11-05 | 2017-12-12 | Hoffmann La Roche | imunoensaio |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| HRP20210547T1 (hr) | 2015-07-10 | 2021-05-14 | Byondis B.V. | Sastavi koji sadrže konjugate lijeka antitijela-duocarmycin |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| CN106467575B (zh) * | 2015-08-18 | 2020-07-31 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物 |
| EP3423831B1 (en) | 2016-03-02 | 2022-05-25 | Waters Technologies Corporation | Identification and quantification of conjugated peptides in antibody drug conjugates by mass spectrometry |
| US11340233B2 (en) * | 2016-03-07 | 2022-05-24 | Pierre Fabre Medicament | Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
| CN116196412A (zh) | 2016-03-15 | 2023-06-02 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| EP3465221B1 (en) * | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| US11092597B2 (en) * | 2017-02-28 | 2021-08-17 | Waters Technoligies Corporation | Devices and methods for analyzing intact proteins, antibodies, antibody subunits, and antibody drug conjugates |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP2020526584A (ja) | 2017-06-28 | 2020-08-31 | ザ ロックフェラー ユニバーシティー | 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用 |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| ES3057444T3 (en) | 2017-08-31 | 2026-03-02 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| BR112020000978A2 (pt) * | 2017-09-08 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | método para determinar uma razão de fármaco para anticorpo em uma amostra compreendendo um conjugado anticorpo-fármaco. |
| WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| JP7165210B2 (ja) | 2018-05-24 | 2022-11-02 | シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | タンパク質の定量分析 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| TW202537643A (zh) | 2018-07-31 | 2025-10-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
| WO2020157381A1 (en) * | 2019-01-29 | 2020-08-06 | Teknologian Tutkimuskeskus Vtt Oy | Methods for screening polypeptides capable of binding specific target molecules and tools related thereto |
| MA55080A (fr) | 2019-02-26 | 2022-01-05 | Inspirna Inc | Anticorps anti-mertk à affinité élevée et utilisations associées |
| CN113613676A (zh) | 2019-03-19 | 2021-11-05 | 中外制药株式会社 | 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库 |
| WO2021016138A1 (en) | 2019-07-19 | 2021-01-28 | Adeptrix Corp. | Multiplexed bead-based analytical assays |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| WO2021080008A1 (ja) * | 2019-10-24 | 2021-04-29 | 国立大学法人 鹿児島大学 | １価ｃｃａｐ生成物の製造方法 |
| CN111366655A (zh) * | 2020-04-01 | 2020-07-03 | 上海中科新生命生物科技有限公司 | 一种基于免疫亲和的贝伐珠单抗生物分析的质谱检测方法 |
| GB202007047D0 (en) * | 2020-05-13 | 2020-06-24 | Binding Site Group Ltd | Mass spectrometry controls |
| EP4229393A4 (en) * | 2020-10-13 | 2024-11-06 | University of Maryland, Baltimore County | Rapid and low-cost sampling for detection of airborne sars-cov-2 in dehumidifier condensate |
| CN120202411A (zh) | 2022-11-18 | 2025-06-24 | 基因泰克公司 | 使用质量标签进行基于ia-lc-ms/ms的测定的信号放大和多重化 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6020208A (en) * | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
| US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| US20020197694A1 (en) * | 2001-06-20 | 2002-12-26 | Weiping Shao | Conjugates of reduced antibodies and biomolecules |
| US7179606B2 (en) | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
| AU2002336842A1 (en) | 2001-11-23 | 2003-06-10 | Syn.X Pharma, Inc. | Hp and apolipoprotein biopolymer markers predictive of alzheimers disease |
| WO2005073732A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Lc/ms method of analyzing high molecular weight proteins |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| AR062435A1 (es) * | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| KR20140116546A (ko) * | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
-
2009
- 2009-05-12 EP EP09747326.8A patent/EP2277044B1/en active Active
- 2009-05-12 WO PCT/US2009/043560 patent/WO2009140242A1/en not_active Ceased
- 2009-05-12 ES ES09747326.8T patent/ES2544971T3/es active Active
- 2009-05-12 US US12/464,250 patent/US8541178B2/en active Active
- 2009-05-12 JP JP2011509610A patent/JP5539971B2/ja active Active
- 2009-05-12 AU AU2009246516A patent/AU2009246516B2/en active Active
- 2009-05-12 CA CA2720124A patent/CA2720124C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2277044A1 (en) | 2011-01-26 |
| AU2009246516A1 (en) | 2009-11-19 |
| US20090286258A1 (en) | 2009-11-19 |
| US8541178B2 (en) | 2013-09-24 |
| CA2720124A1 (en) | 2009-11-19 |
| JP2011524001A (ja) | 2011-08-25 |
| EP2277044B1 (en) | 2015-06-17 |
| JP5539971B2 (ja) | 2014-07-02 |
| ES2544971T3 (es) | 2015-09-07 |
| WO2009140242A1 (en) | 2009-11-19 |
| AU2009246516B2 (en) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2720124C (en) | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry | |
| US7662936B2 (en) | Mass spectrometry of antibody conjugates | |
| US8679767B2 (en) | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides | |
| US20240012003A1 (en) | Multiplexed total antibody and antibody-conjugated drug quantification assay | |
| CN109313200B (zh) | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 | |
| Kaur et al. | Mass spectrometry of antibody–drug conjugates in plasma and tissue in drug development | |
| Wei et al. | Sample Preparation for LC‐MS Bioanalysis of Antibody–Drug Conjugates | |
| Xue et al. | Mass Spectrometry‐Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development | |
| HK1262578A1 (en) | Multiplexed total antibody and antibody-conjugated drug quantification assay | |
| HK40003990A (en) | Bioanalytical method for the characterization of site-specific antibody-drug conjugates | |
| HK40003990B (en) | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140122 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250424 |